dievini Hopp co-leads EUR 53.8M immatics round

immatics biotechnologies GmbH (Tuebingen, Germany) raised EUR 53.8 million ($70.5 million) in a series C round co-led by new investors MIG Funds and AT Impf and existing investor dievini Hopp BioTech. Existing investors Wellington Partners; Grazia Equity; EMBL Ventures; Renaissance PME; Mona Lisa Capital; KfW; National Technology Enterprises; Merifin Capital; Zepta; Beacon Hill; and PB Invest as well as undisclosed private investors also participated. ...